Place of pharmacotherapy in post-traumatic stress disorder

Lancet

Volumn 354, Issue 9188, 1999, Pages 1404-1405

  Turner, Stuart ^a  

^a CAMDEN AND ISLINGTON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; FLUOXETINE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

HUMAN; NOTE; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL;

EID: 0033598610     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(99)00245-7     Document Type: Note

References (7)

1. Diagnostic and statistical manual of mental disorders, 4th edn, DSM-IV. Washington DC: American Psychiatric Association, 1994.
2. Kessler R.C., Sonnega A., Bromet E.J., Hughes M., Nelson C.B. Posttraumatic stress disorder in the National Comorbidity Survey. Arch Gen Psychiatry. 52:1995;1048-1060.
3. Yehuda R, ed. Neuroendocrinology of trauma and posttraumatic stress disorder. In: Psychological trauma. Washington, DC: American Psychiatric Press, 1998: 97-131.
4. Van Etten M.L., Taylor S. Comparative efficacy of treatments for post-traumatic stress disorder: a meta-analysis. Clin Psychol Psychother. 5:1998;126-144.
5. Shapiro F. Eye movement desensitization and reprocessing. 1995;Guilford Press, New York.
6. Foa EB, Davidson JRT, Frances A. The Expert Consensus Guideline Series: treatment of posttraumatic stress disorder. J Clin Psychiatry 1999; 60: (suppl 16) and http://www.psychguides.com (accessed on Oct 18, 1999).
7. Connor K.M., Sutherland S.M., Tupler L.A., Malik M.L., Davidson J.R.T. Fluoxetine in post-traumatic stress disorder: randomised, double-blind study. Br J Psychiatry. 175:1999;17-22.